Austin, TX — January 25, 2025

Akexis’ Principal Investigator (PI), Dr. Andrew Hendifar, presented the results of a pivotal proof-of-concept cancer cachexia study at the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium. The presentation highlighted findings from a paper co-authored by Akexis Founder and CEO, Dr. Lingbing Zhang, which explores an innovative therapeutic approach for treating advanced-stage cancers.

The presentation, titled "Effect of ketorolac on serum GDF-15 and IL-8 in patients with pancreatic cancer with cachexia" (Abstract ID: 241654), showcased breakthrough data on targeting immune dysfunction in cancer cachexia, a debilitating condition that affects many late-stage cancer patients. The findings represent a significant step forward in addressing immune imbalances linked to cachexia and advancing care for patients with gastrointestinal cancers.

"Presenting these findings at ASCO is a testament to the collaborative work between Akexis founder, Dr. Lingbing Zhang and Cedars-Sinai’s dedicated oncology team," said Dr. Hendifar. "Our study provides compelling insights into novel therapeutic approaches, potentially improving quality of life for patients experiencing the devastating effects of cancer cachexia."

Dr. Zhang added, "This work validates Akexis's commitment to transforming cancer care through innovative treatments that target the destructive immune dysregulation. Our collaboration with leading clinical experts like Dr. Hendifar is essential to achieving this mission."

Akexis remains focused on advancing innovative cancer therapeutics designed to improve outcomes for patients with late-stage cancer. The company continues to invest in groundbreaking research and partnerships that push the boundaries of  late-stage cancer care. 

For more information on Akexis and its research initiatives, visit www.akexis.com.

About Akexis:
Akexis is a biotechnology company dedicated to developing transformative cancer therapeutics. Led by a team of seasoned scientists, clinicians, and innovators, Akexis is committed to advancing solutions that address the highly unmet needs of late-stage cancer patients. Akexis is on a mission to save lives and conquer late-stage cancer through groundbreaking science and the development of first-in-class therapies where no options currently exist. Our vision is to revolutionize late-stage cancer by pushing boundaries and transforming it from a terminal disease to a manageable lifelong condition. Through innovative approaches and tailored treatments, we aim to empower patients with new possibilities for long-term remission and improved quality of life. For inquiries on partnering and investing please contact Suzanne Kennedy at skennedy@akexis.com.